The Rise of Personalized Medicine: What It Means for Patients

For most of medical history, treatment has been designed for the average patient. A drug is tested on thousands of people, an average benefit is calculated, and everyone with the diagnosis receives roughly the same prescription. It works for many, partially for some, and not at all for others — and until recently, there was no way to know in advance which group you belonged to.

Personalized medicine is the attempt to answer that question before treatment rather than after. It is not a futuristic concept; parts of it are already routine, including in Bangladesh.

What personalized medicine actually means

Personalized medicine — also called precision medicine — means selecting treatment based on characteristics specific to an individual patient rather than to the disease category alone.

Those characteristics can be genetic, but not only genetic. They include the molecular profile of a tumour, inherited variations that affect how a person metabolises drugs, biomarkers in blood or tissue, family history, and increasingly the continuous data from home monitoring.

The core shift is from what disease does this patient have to what kind of this disease does this patient have, and which treatment will their biology respond to.

Where it is already standard

The clearest example is cancer treatment, and it is worth understanding because it is not theoretical.

Breast cancer is no longer treated as a single disease. Tumours are tested for hormone receptor status and HER2 status, and the treatment differs fundamentally depending on the result. A HER2-positive tumour receives a targeted therapy that would be useless against a HER2-negative one. This testing is routine at major oncology centres in Bangladesh.

Lung cancer follows the same logic. Tumours are tested for specific mutations, and patients with certain mutations receive targeted oral drugs rather than conventional chemotherapy — with markedly different tolerability and outcomes.

Blood cancers, colorectal cancer, and several others now have established molecular subtypes guiding therapy. In oncology, personalized medicine is not the future. It is current practice.

Beyond cancer

Other applications are expanding.

Pharmacogenomics examines how inherited differences affect drug response. Some patients metabolise particular drugs so rapidly that a standard dose is ineffective; others so slowly that a standard dose is toxic. Warfarin dosing, certain psychiatric medications, and some pain medications are affected by this. Testing is not yet widespread in Bangladesh, but the clinical principle explains something patients often notice — that a medicine which helps a relative does nothing for them.

Inherited disease risk. Testing for BRCA mutations, familial hypercholesterolaemia, and thalassaemia carrier status changes screening intensity and, in some cases, preventive action. Thalassaemia carrier screening has particular relevance in Bangladesh given carrier prevalence, and is directly useful for couples planning a family.

Infectious disease. Drug susceptibility testing in tuberculosis is a form of precision medicine — it identifies which drugs a specific strain will respond to rather than assuming the standard regimen works.

What it means for an ordinary patient

The realistic effects for most people are not exotic.

Fewer wasted treatments. If testing shows a drug will not work for your tumour type, you avoid months of side effects for no benefit. In a system where patients pay out of pocket, avoiding an ineffective expensive treatment is a direct financial protection as well as a clinical one.

Better targeted screening. A known family history of breast, colorectal, or cardiac disease should change when your screening begins and how often it repeats. This costs almost nothing and is the most accessible form of personalization available today.

More informed choices. When a test shows a particular treatment has a low probability of benefit, patients and families can make decisions about aggressive treatment versus quality of life with better information.

Fewer adverse reactions. As pharmacogenomic testing becomes more available, dosing can be adjusted to individual metabolism rather than adjusted after a bad reaction.

The honest limitations

Personalized medicine is oversold in popular coverage, and patients deserve a clear-eyed view.

Cost is the main barrier. Molecular testing is expensive, and the targeted therapies it identifies are often more expensive still. A test that identifies a treatment the patient cannot afford has limited value, and that situation is common.

Availability is uneven. Advanced molecular pathology is concentrated in a few centres in Dhaka. Samples sent abroad add cost and delay.

Not every condition has a personalized approach. For a great many diseases, the standard treatment is standard because it works well for nearly everyone, and no test would change it.

Direct-to-consumer genetic tests sold online are largely unhelpful for clinical decisions. Ancestry-focused kits and wellness gene reports have little medical validity, and interpreting a raw genetic result without a clinician is a good way to generate anxiety about risks that may not apply to you.

The data foundation

There is a less glamorous component of personalized medicine that matters more for most patients than any genetic test: an accurate, longitudinal record of their own body.

Blood pressure over five years. Blood sugar trends. Weight trajectory. Which medications worked and which caused side effects. Family history, documented properly.

This is personalization available to everyone at negligible cost, and it is what most patients lack. Bangladesh’s National Digital Health Strategy and its Health ID initiative aim to build exactly this foundation — records that follow the patient rather than sitting in a drawer at one clinic.

At the household level, the same principle applies through home monitoring. Accurate readings taken consistently create the personal baseline against which anything abnormal becomes visible. PROMIXCO Healthcare Limited supplies the devices this depends on — glucose monitoring systems, patient monitors, and the consumables that keep them accurate — to households and clinics across Bangladesh.

Knowing that your normal resting blood pressure is 118/76 is a genuinely personalized medical fact. Most people do not have it.

Questions worth asking your doctor

If personalization is relevant to your situation, a few questions get to the point quickly.

For a cancer diagnosis: has the tumour been tested for markers that would change treatment, and is that testing available here or does the sample need to be sent elsewhere? What does the test cost, and what would change based on the result?

For a strong family history: does my family history change what should be screened and when? Should any family members be tested?

For medication that is not working or causing side effects: is there a known variation in how people respond to this drug, and is an alternative appropriate?

For any long-term condition: what should I be recording at home so that my treatment can be adjusted to me rather than to the average?

The realistic picture

Personalized medicine in 2026 is neither the revolution described in marketing material nor an irrelevance. In oncology it is already changing outcomes. In inherited risk and carrier screening it offers practical value to Bangladeshi families today. In pharmacogenomics it is arriving gradually.

For most patients, the highest-value personalization available right now is simpler than genomics: know your family history, keep accurate records of your own measurements over time, and make sure your doctor has both. That is where individualised care actually begins.